Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma
Conditions
Recurrent Diffuse Large B-Cell Lymphoma · Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified · Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements · Recurrent High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements · Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified · Recurrent Nodal Marginal Zone Lymphoma · Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma · Refractory Diffuse Large B-Cell Lymphoma · Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified · Refractory High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements · Refractory High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements · Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified · Refractory Nodal Marginal Zone Lymphoma · Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
Contact: Study coordinator (Office of Clinical Research) · OCRReferral@health.ucdavis.edu · 916-382-6970Contact: Principal Investigator (Joseph M. Tuscano)
Study leads
Joseph M Tuscano
Study Chair
University of California, Davis